Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Abstract Background Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival among metastatic RMS patients has remained dismal yet unimproved for years. We previously identified the class I-specific histone deacetylase inhibitor, entinostat (ENT), as...

Full description

Bibliographic Details
Main Authors: Narendra Bharathy, Noah E. Berlow, Eric Wang, Jinu Abraham, Teagan P. Settelmeyer, Jody E. Hooper, Matthew N. Svalina, Zia Bajwa, Martin W. Goros, Brian S. Hernandez, Johannes E. Wolff, Ranadip Pal, Angela M. Davies, Arya Ashok, Darnell Bushby, Maria Mancini, Christopher Noakes, Neal C. Goodwin, Peter Ordentlich, James Keck, Douglas S. Hawkins, Erin R. Rudzinski, Atiya Mansoor, Theodore J. Perkins, Christopher R. Vakoc, Joel E. Michalek, Charles Keller
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Skeletal Muscle
Subjects:
Embryonal rhabdomyosarcoma (eRMS)
Entinostat
Vincristine
HDAC3
Patient-derived xenograft (PDX)
Online Access:http://link.springer.com/article/10.1186/s13395-019-0198-x

Internet

http://link.springer.com/article/10.1186/s13395-019-0198-x

Similar Items